Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PB1046 in Pulmonary Arterial Hypertension
NCT03315507Phase 1Completed
- Sponsor
- PhaseBio Pharmaceuticals
- Start
- Oct 2017
- Primary completion
- Aug 2019
- Modality
- Peptides, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pemziviptadil in pulmonary arterial hypertension (PAH), sponsored by PhaseBio Pharmaceuticals. Primary endpoints: Adverse Events, Blood Pressure and 5 more. Started Oct 2017; status: completed.
02
Drugs
pemziviptadil
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT03315507.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03315507.